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The cognitive and behavioural deficits caused by traumatic brain injury (TBI) to the immature brain are
more severe and persistent than TBI in the mature brain. Understanding this developmental sensitivity is
critical as children under four years of age sustain TBI more frequently than any other age group.
Microglia (MG), resident immune cells of the brain that mediate neuroinflammation, are activated
following TBI in the immature brain. However, the type and temporal profile of this activation and the
consequences of altering it are still largely unknown.
In a mouse model of closed head weight drop paediatric brain trauma, we characterized i) the temporal
course of total cortical neuroinflammation and the phenotype of ex vivo isolated CD11B-positive
microglia/macrophage (MG/MU) using a battery of 32 markers, and ii) neuropathological outcome 1
and 5 days post-injury. We also assessed the effects of targeting MG/MU activation directly, using
minocycline a prototypical microglial activation antagonist, on these processes and outcome.
TBI induced a moderate increase in both pro- and anti-inflammatory cytokines/chemokines in the
ipsilateral hemisphere. Isolated cortical MG/MU expressed increased levels of markers of endogenous
reparatory/regenerative and immunomodulatory phenotypes compared with shams. Blocking MG/MU
activationwithminocycline at the time of injury and 1 and 2 days post-injury had only transient protective
effects, reducing ventricular dilatation and cell death 1 day post-injury but having no effect on injury sever-
ity at 5 days.
This study demonstrates that, unlike in adults, the role of MG/MU in injurymechanisms following TBI in
the immature brainmay not be negative. An improved understanding ofMG/MU function in paediatric TBI
could support translational efforts to design therapeutic interventions.
 2016 The Author(s). Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction et al., 2012). Unfortunately, the cognitive and behavioural deficitsTraumatic brain injury (TBI) is the most common injury leading
to significant lifelong disability that occurs in children (Stanleycaused by traumatic brain injury (TBI) to the immature brain are
more severe and persistent than those observed following compa-
rable injuries to the mature (adult) brain (Anderson et al., 2005;
Ewing-Cobbs et al., 2006; Hessen et al., 2007; Rivara et al., 2012)
(reviewed in (Giza et al., 2007)) with injury in an experimental set-
ting progressing into a chronic brain disorder (Ajao et al., 2012;
Kamper et al., 2013). This is in contrast to Kennard’s Principle that
the immature brain has superior potential for repair (Bennet et al.,
2013). This is of particular concern as children under the age of(2016),
2 V. Chhor et al. / Brain, Behavior, and Immunity xxx (2016) xxx–xxxfour years sustain TBI more frequently than any other age group
(Koepsell et al., 2011) and in children under the age of 2 years,
the rates of TBI serious enough to require intensive care support
are as high as 50 per 100,000 (Keenan et al., 2003). A developmen-
tal sensitivity to TBI as seen in humans is also observed in a rodent
model of TBI, where within the first 30 days of life, injury is max-
imal when TBI is caused at postnatal day 7 (P7) (Bittigau et al.,
1999). In addition, during the first three postnatal weeks, rodents
display a heightened sensitivity to excitotoxicity (Ikonomidou
et al., 1999). In mouse and humans this period is when develop-
mental processes such as maximal brain growth, synaptogenesis
and myelination occur.
In the paediatric population, TBI is caused by injuries and
insults, which include acceleration/deceleration injuries (shaken
baby syndrome) and contusion injuries (direct skull impact)
(Pinto et al., 2012). Contusion injuries are the prevailing form of
non-inflicted injuries and also represent a large proportion of
inflicted injuries (Pinto et al., 2012). The primary injury process
in TBI is mechanical damage (i.e. shear forces inducing vascular
damage and bleeding), followed immediately by mast cell degran-
ulation (Stokely and Orr, 2008), and secondary pathological pro-
cesses, including excitotoxicity, ischemia, mitochondrial
dysfunction, activation of matrix metalloproteinases (MMPs) and
activation of caspases leading to apoptosis (Xiong et al., 2013).
These secondary injury processes induce neuroinflammation,
which itself has the potential to be neurotoxic (Hagberg et al.,
2012), but which is poorly understood in the immature brain fol-
lowing TBI.
Microglia (MG) are the central regulators of neuroinflammation,
involved in the pathological processes of the majority of acute and
chronic brain injuries, such as stroke, Alzheimer’s disease and mul-
tiple sclerosis (for review see (Prinz et al., 2011)). Thus MG are log-
ical candidates to mediate neuropathological changes following
TBI in the immature brain. MG possess enormous functional plas-
ticity that allows them to participate in both injury and repair, as
reviewed in (Colton and Wilcock, 2010; Ransohoff and Perry,
2009). The nomenclature of these functional activation states (phe-
notypes) of MG has been simplified to facilitate their description
and a common nomenclature includes classic pro-inflammatory
or cytotoxic, anti-inflammatory or reparatory/regenerative and
immunomodulatory phenotypes.
There are specific differences in the immune and inflammatory
responses to injury between neonatal and adult humans and
experimental animals (Copland et al., 2004; Giza et al., 2007;
Schultz et al., 2004; Zhu et al., 2005), including in microglia respon-
siveness (Butovsky et al., 2014). Studies of neuroinflammatory pro-
file and MG activation states have recently been published in adult
models of TBI (Bye et al., 2007; Kumar et al., 2015) but it is
unknown how microglia would respond to a similar injury to the
developing brain. As such, this study investigates for the first time
the characteristics of MG- driven neuroinflammation in a mouse
model of paediatric TBI. Furthermore, as a proof-of-concept, we
aimed to assess the effects of modulating MG activity on injury
severity using the immunomodulatory tetracycline minocycline.
Minocycline reportedly has strongly anti-inflammatory actions
and has been used to reduce MG activation and injury with success
in numerous pathological models (see Table 1 and review,
(Garrido-Mesa et al., 2013)).2. Materials and methods
2.1. Animals
Study ethics were approved by the Bichat and Robert Debré
Hospital ethics committee (No 2011-14/676-0050) and adheredPlease cite this article in press as: Chhor, V., et al. Role of microglia in a mous
http://dx.doi.org/10.1016/j.bbi.2016.11.001to the European Union Guidelines for the Care and Use of Animals.
Procedures were typically carried out between 10am and 1 pm
(light phase: 7am-7 pm daily), all animals were monitored daily
during experimentation. A single animal represents an experimen-
tal unit with groups spread between and across litters where
possible and each litter had an approximate 50–50% spread of
males-females. Specifically, data in Fig. 2 are derived from 6 litters;
Fig. 3 derived from 24 litters; Figs. 4, 5 and 7 derived from 6 litters
each; Fig. 6 derived from 6 litters. Animals were housed in
Plexiglas cages (30x18x15 cm) together with littermates and their
dam for the whole of the experiment. Animals had access to
standard chow and water ad libitum and bedding was wood-chips
with shredded paper for nesting (Pharmaserv, France).
2.2. Traumatic brain injury model and experimental procedure
Postnatal day 7 (P7; weight 4–5 g) OF1 mice (Charles River,
L’Arbresle, France) of both sexes were randomly (alternating ani-
mals) allocated to TBI, control or TBI+ treatment (phosphate buf-
fered saline [PBS] or minocycline) groups. The study protocol is
detailed in Fig. 1. A dose of 45 mg/kg of minocycline was chosen
based on its prior use in models of adult TBI, stroke and paediatric
excitotoxic lesion, see Table 1. In a separate experimental work-
space within the animal facility, mice were anesthetized with
isoflurane (8% induction) and subjected to a closed head weight–
drop head trauma at P7 in a model as described previously
(Kaindl et al., 2007). In brief in a process lasting no more than
3 min, the skull was fixed into a stereotaxic frame, the skull surface
exposed with a skin incision and the impact device was oriented
parallel to the parietal bone with the centre of the foot plate
(2 mm diameter) positioned 2 mm anterior and 1 mm lateral to
lambda on the parietal bone. The foot-plate was first allowed to
touch the skull and was then further depressed by 0.5 mm. The
impact device consisted of a hollow stainless-steel cylinder
20 cm in length, perforated at 1 cm intervals to prevent air com-
pression, and guiding a 10 g weight falling from a height of
10 cm onto the foot-plate (2.0 mm in diameter). The contusion
impact was delivered unilaterally to the left side of the skull, the
same operator conducted all experiments and cortical contusions
were of comparable severity in all animals. Body temperature
was kept constant via the use of a heating pad maintained at
37 C until pups were returned to their dams at approximately
15 min post-TBI. Sham animals were anesthetized and an incision
made in their scalp, this was then sutured and animals were recov-
ered after 3 min in line with the time taken for the TBI procedure.
Minocycline (45 mg/kg in PBS: Sigma, Lyon, France) (Cai et al.,
2006; Dommergues et al., 2003) or PBS alone was injected
intraperitoneal immediately following TBI, and at 24 and 48 h
post-TBI, depending on the protocol. A group of sham minocycline
was not included in this study as the specific aim was to investi-
gate the effects of modulating the microglial activation state asso-
ciated with TBI. Furthermore, minocycline has been widely
reported to have no effect on microglial gene expression in a basal
state (Kobayashi et al., 2013; Scholz et al., 2015).
2.3. Tissue preparation, and histology
One or five days after TBI, animals were euthanatized via an
overdose of pentobarbital and decapitation and brainswere immer-
sion fixed (formol 4% for 5 days), embedded in paraffin and
coronally sectioned (16 lm) from the frontal pole to the occipital
lobes. Ventricular area was determined as described previously
(Kaindl et al., 2007; Moretti et al., 2016) on cresyl-violet-stained
sections. In short, the border of each lateral ventricle from three
serial sections spanning the hippocampus and midstriatum was
outlined, then the cross-sectional ventricular areas weree model of paediatric traumatic brain injury. Brain Behav. Immun. (2016),
Table 1
Summary of selected studies investigating the neurotherapeutic effects of minocycline.
Study Animal Injury Dose Regime Cell death / Lesion
Volume
MG number Outcome
Dommergues
et al.
(2003)
P5
mouse
Excitotoxic 45 mg/kg Twice daily from P5-P7 Decreased Cleaved Caspase-3 at
+1 day and decreased lesion volume
at +5 days
Decreased numbers of Lectin+ MG Decreased lesion volume at +5 days
Fox et al.
(2005)
P7 rat MCAO 45 mg/kg +2 h & +2 h, or +8 h & +18 h Decreased lesion volume at +1 day No change in ED1+ MG numbers No improvement in lesion volume at +7 days
Yang et al.
(2015)
Adult
rat
MCAO 5 mg/kg +5 min Decreased infarct on MRI 60% decreased (Increased anti-
inflammatory type MG)
Improvements on MRI at 4 week
Cai et al.
(2006)
P4 rat HI 45 mg/kg 12 h before, immediately after &
daily for 3 days
Decreased pyknosis at +4 days 50% decrease in numbers of lectin
positive MG
Decreased loss of mature oligodendrocytes and
myelin at +2 weeks
Lechpammer
et al.
(2008)
P6 rat HI 50 mg/kg Immediately following HI Decreased white matter injury at
+3 days
Decreased numbers of CD68+ &MHCII+
cells at +3 days
Arvin et al.
(2002)
P7 rat HI 22.5–45 mg/kg Immediately before or +3 h Decreased lesion volume at +7 days – Decreased lesion volume at +7 days
Tsuji et al.
(2004)
P7
mouse
HI 22–135 mg/kg (1) Twice in first 24 h (45 mg/
kg) & twice in the next 24 h
(23 mg/kg), or
(2) Twice in first 24 h (135 mg/
kg) & twice in the next 24 h
(68 mg/kg), or
(3) Single dose 12 h before HI
(45 mg/kg)
Exacerbated total injury score for all
treatments (1–3) at +7 days
– Mouse: Exacerbated total injury score for all
treatments (1–3) at +7 days
P7 rat 45 mg/kg (4) Immediately before HI, or(5)
12 h before HI
Decreased total injury score for both
treatments (4–5) at +7 days
– Rat: Decreased total injury score for both
treatments (4–5) at +7 days
Hanlon et al.
(2016)
P11 rat Repeated
TBI (CCI)
45 mg/kg Once immediately after the
third and final TBI
No change in fluro-jade B+ cell
number at +3, +7 & +21 days
No change Exacerbated defects in retention tasks. No
improvements in tissue loss or spatial memory
defects at +21 days.
Bye et al.
(2007)
Adult
mouse
TBI (CCI) 45 mg/kg +30 min & every 12 h for 3 days Decreased at +1 day, no change at
+4 days
Decreased amoeboid ED1+ MG No improvement in motor function at +1 week
Homsi et al.
(2010)
Adult
mouse
TBI (CCI) 90-45 mg/kg +5 min (90 mg/kg), +3 h & +9 h
(45 mg/kg)
50% decrease in cortical tissue loss 50% Decrease in CD11b+ MG/MU Improvement in locomotor hyperactivity at
+8 weeks
Current study P7
mouse
TBI (WD) 45 mg/kg Immediately after & at +24 h &
+48 h
Decreased cleaved caspase-3+ cell
numbers, decreased ventricular
volume at +1 day
15% decrease in numbers of Iba1+ MG
(minimal change in activation by gene
expression)
No improvements in neuropathology at +5 days
HI, hypoxic/ischemic. CCI, controlled cortical impact. WD, weight drop.
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Fig. 1. Schematic representation of the experimental procedures including admin-
istration of drugs and tissue collection, and injury distribution. Injury is indicated
by the expression of CCasp3 at 1 day (+1d) and 5 days (+5d) following TBI. Slightly
increased areas of labelling shown by orange stars, moderate increases by red stars
and intense changes shown as blocks of red. (For interpretation of the references to
colour in this figure legend, the reader is referred to the web version of this article.)
4 V. Chhor et al. / Brain, Behavior, and Immunity xxx (2016) xxx–xxxdetermined using ImageJ software (version 1.43; National Institute
of Health, Bethesda, Md., USA) and the ratio between the left (ipsi-
lateral) and right (contralateral) ventricular areas determined. All
tissue processing and analyses were carried out by investigators
blind to the treatment group due to coding of the brains and cover-
ing of the codes during analysis. There were no differences in the
ventricular area of the contralateral hemisphere between sham
and TBI mice. Immunohistochemistry (IHC) was performed as pre-
viously described (Fleiss et al., 2012), and the antibodies used
included: rabbit monoclonal anti-ionized calcium binding adaptor
molecule-1 (Iba-1; 1:1000, Wako Chemicals USA, 019-19741), Rab-
bit monoclonal anti-cleaved caspase 3 (CCasp3; 1:200, Cell Sig-
nalling, 9661), mouse monoclonal anti-myelin basic protein
(MBP; 1:500, Millipore, MAB382) and mouse monoclonal anti-
microtubule-associated protein 2 (MAP2; 1:2000, Sigma, M4403).
After overnight incubation with primary antibodies and washing,
sections were incubated with appropriate secondary antibodies
(1:200; Vectorlabs, California, USA).2.4. Analysis of neuropathology
Ventricular volume was assessed by measuring the area of the
ipsilateral and contralateral ventricles and expressed as percentage
of change compared to the contralateral values. Iba-1-positive and
CCasp3-positive cells were counted in the parietal cortex, hip-
pocampal CA1 region and striatum of the traumatized hemisphere,
on two images captured using a Leica DM6000 B microscope (Leica
Microsystems Ltd.) and a 10X objective at the level of maximum
lesion (approximately 1.50 mm from bregma). Counts were car-
ried out using Image J and cell numbers within a given region
expressed as cells/mm2. The area of MAP2 and MBP immunolabel-
ing was measured at 4–6 levels per brain (one 16 lm-thick serial
section every 576 lm) as previously described (Fleiss et al.,
2012). Volumes of MAP2 and MBP immunolabeling were calcu-
lated from area measurements according to Cavalieri’s principle
using the following formula: V = SA  P  T, where V is total
volume, SA is the sum of the areas measured, P is the inverse of
the sampling fraction and T is the section thickness. Volume loss
was estimated by the difference in calculated volumes between
the contralateral (right) and the ipsilateral hemispheres (left).Please cite this article in press as: Chhor, V., et al. Role of microglia in a mous
http://dx.doi.org/10.1016/j.bbi.2016.11.0012.5. CD11B-antibody-coupled magnetic cell isolation
At different time-points following TBI (2, 6, 14, 24 h and 5 days),
cells positive for CD11B (cluster of differentiation 11 beta, a marker
for MU and MG), were extracted using the antibody-coupled
magnetic bead system (MACS) following the manufacturer’s rec-
ommendations (Miltenyi Biotec, Bergisch Gladbach, Germany)
and as previously reported (Schang et al., 2014). In brief, the olfac-
tory bulbs and cerebella were removed and the hemispheres
mechanically and enzymatically digested using the Neural Tissue
Dissociation Kit (Miltenyi Biotec, Germany). Three or four hemi-
spheres were pooled for each sample to ensure sufficient RNA
quantities. In a preliminary analysis, comparisons of MG/MU
activation and cytokine gene expression between left and right
sham hemisphere did not show any differences and samples were
pooled. Homogenized and digested tissue was incubated with
magnetic coupled anti-CD11B antibodies and CD11B-positive cells
were separated in a magnetic field before being counted and frozen
at 80 C. The purity of separated cells was assessed using quanti-
tative real-time polymerase chain reaction (qRT-PCR) for glial fib-
rillary acidic protein (GFAP; astrocytes), MBP (oligodendrocytes),
neuronal nuclear antigen (NeuN; neurons) and CD11B (MG/MU),
and showed levels of contamination less than 5%. We have
described the CD11B-positive population extracted from the brain
as MG/MU as we cannot exclude a contribution of macrophages to
the cell population (Hsieh et al., 2013).
2.6. RNA extraction and quantification of gene expression by real-time
qPCR
MG/MU qRT-PCR, primer design, and PCR setups were similar
to that previously described (Chhor et al., 2013; Husson et al.,
2005; Schang et al., 2013). In brief, RNA was extracted using Qiagen
RNA extraction columns as per the manufacturers instructions,
including initial homogenisation in Trizol (Invitrogen). RNA purity
was verified using a nanodrop. Reverse transcription was per-
formed using an iScript RT kit (Biorad) as per manufacturers
instructions. PCR reactions were setup on a loading robot in 384
well plates with Sybr green from Biorad as per recommended
protocol. Primer sequences are given in Table 2. Gapdh
(glyceraldehyde-3-phosphate dehydrogenase) was used to nor-
malize the quantitative experiments based on prior reference-
gene suitability testing and we verified for each experiment that
the raw Gapdh values were not significantly different between
groups. The relative quantities are expressed as the specific ratio
between the gene of interest and the reference gene. Genes were
classified as cytotoxic, repair/regeneration or immunomodulatory
based on the literature (Colton and Wilcock, 2010; Ransohoff and
Perry, 2009) and previous characterization in our lab (Chhor
et al., 2013).
2.7. Protein extraction procedure and multiplex cytokine/chemokine
assay
Frozen cortices from 6, 14 and 24 h post-TBI were homogenized
in 0.1 M PBS, and extracts sonicated in ice-cold homogenization
buffer (3 mM ethylenediaminetetraacetic acid [EDTA] and 1%
protease inhibitor cocktail, [P8340, Sigma] in 0.1 M PBS) and cen-
trifuged (800xg for 10 min). The supernatant was collected and
stored at 80 C. Protein concentrations were determined via a
bicinchoninic acid (BCA) assay. After thawing on ice, supernatants
were centrifuged briefly to remove particulates (300g for 10 min).
Cytokine and chemokine levels were measured using a 96-well
magnetic plate assay on a Bio-Plex 200 according to the manufac-
turer’s instructions (BioRad laboratories, Marnes la Coquette,
France). Cytokines and chemokines measured included interleukinse model of paediatric traumatic brain injury. Brain Behav. Immun. (2016),
Table 2
Primer sequences and NCBI references.
Gene Sense Antisense NCBI Reference
Gapdh GGC CTT CCG TGT TCC TAC TGT CAT CAT ATC TGG CAG GTT NM_008084.2
iNos CCC TTC AAT GGT TGG TAC ATG G ACA TTG ATC TCC GTG ACA GCC NM_010927.3
CD32 CTG GAA GAA GCT GCC AAA AC CCA ATG CCA AGG GAG ACT AA NM_010187.2
CD86 GAG CGG GAT AGT AAC GCT GA GGC TCT CAC TGC CTT CAC TC NM_019388.3
Ptgs2 TCA TTC ACC AGA CAG ATT GCT AAG CGT TTG CGG TAC TCA TT NM_011198.3
CD206 CTT CGG GCC TTT GGA ATA AT TAG AAG AGC CCT TGG GTT GA NM_008625.2
Arg1 GTG AAG AAC CCA CGG TCT GT GCC AGA GAT GCT TCC AAC TG NM_007482.3
Lgals3 GAT CAC AAT CAT GGG CAC AG ATT GAA GCG GGG GTT AAA GT NM_010705.3
Igf1 TGG ATG CTC TTC AGT TCG TG GCA ACA CTC ATC CAC AAT GC NM_010512.4
Sphk1 TCC AGA AAC CCC TGT GTA GC CAG CAG TGT GCA GTT GAT GA NM_001172475.1
Il1rn TTG TGC CAA GTC TGG AGA TG TTC TCA GAG CGG ATG AAG GT NM_031167.5
Il4ra GGA TAA GCA GAC CCG AAG C ACT CTG GAG AGA CTT GGT TGG NM_001008700.3
Socs3 CGT TGA CAG TCT TCC GAC AA TAT TCT GGG GGC GAG AAG AT NM_007707.3
IL1b GGG CCT CAA AGG AAA GAA TC TCT TCT TTG GGT ATT GCT TGG NM_008361.3
IL-6 CAA AGC CAG AGT CCT TCA GA GCC ACT CCT TCT GTG ACT CC NM_031168.1
IL10 CTC CCC TGT GAA AAT AAG AGC GCC TTG TAG ACA CCT TGG TC NM_010548.2
IL-12a TCA CAA CCA TCA GCA GAT CA TGC AGA GCT TCA TTT TCA CTC NM_001159424.1
IL-12b ATC CAG CGC AAG AAA GAA AA AAT AGC GAT CCT GAG CTT GC NM_008352.2
IL-18 TTC GTT GAC AAA AGA CAG CC TAT CAG TCT GGT CTG GGG TTC NM_008360.1
Tnfa GCC TCT TCT CAT TCC TGC TT AGG GTC TGG GCC ATA GAA CT NM_013693.3
Cxcl1 GCA CCC AAA CCG AAG TCA TA AGG TGC CAT CAG AGC AGT CT NM_008176.3
Cxcl10 GGG TAA AGG GAG GTG GAG AG GCT TAT TGA AAG CGG TGA GC NM_021274.2
Ccl2 CAT CCA CGT GTT GGC TCA TCA TTG GGA TCA TCT TGC TG NM_011333.3
Ccl3 TTT TGA AAC CAG CAG CCT TT CTG CCT CCA AGA CTC TCA GG NM_011337.2
Mbp CCG GAC CCA AGA TGA AAA C CTT GGG ATG GAG GTG GTG T NM_010777.3
Gfap CTC CTG GTA ACT GGC CGA CT AAG CCA AGC ACG AAG CTA AC NM_010277.3
NeuN CGA TGC TGT AGG TTG CTG TG CAG ATA TGC TCA GCC AGC AG NM_001039168.1
CD11B CTG GTG CTC TTG GCT CTC AT GGC AGC TTC ATT CAT CAT GT NM_001082960.1
V. Chhor et al. / Brain, Behavior, and Immunity xxx (2016) xxx–xxx 5(IL) IL-1a, IL-1b, IL-3, IL-4, IL-5, IL-6, IL-9, IL-10, IL-12(p40), IL-12
(p70), IL-13, IL-17, granulocyte colony stimulating factor (G-CSF),
interferon (IFN) c, tumor necrosis factor (TNF) a, chemokine C-X-
C motif ligand (CXCL) 1 (KC), chemokine ligand (CCL) 2 (also
known as MCP-1), CCL3 (also known as MIP1a), CCL4 (also known
as MIP1b) and CCL5 (also known as RANTES). All samples were run
in duplicate and data analysed with Bio-Plex Manager 6.0 software.
Cytokines and chemokines were classified as cytotoxic, repair/
regeneration or immunomodulatory based on the literature
(Colton and Wilcock, 2010; Ransohoff and Perry, 2009) and previ-
ous characterization in our lab (Chhor et al., 2013).
2.8. Statistics
Data are presented as means ± SEM. No animals were excluded
from any analysis. Numbers in each experiment are indicated
within the text, or in the figure legends. Sample sizes were based
on calculations of effect sizes from previous studies on this model
within the laboratory (Kaindl et al., 2007). For two experimental
groups, t-tests or Mann Whitney U test were performed. Where
more than two experimental groups were compared an ANOVA
was performed and when this was significant (p < 0.05) a Bonfer-
roni post-test was performed. The appropriate statistical test was
chosen based on data normality (Kolmogorov-Smirnov test). The
statistical test performed on each data set (using GraphPad 5.0
software [San Diego, CA, USA]) is indicated in the figure legend
or within the text.3. Results
3.1. TBI increases early cell death, microglial number and cortical
cytokine / chemokine levels
Following TBI, CCasp3-positive cells were present in the
underlying cortex, thalamic nuclei, hippocampal dentate gyrus,
subiculum and striatum, and increased numbers of Iba-1 positive
cells were observed mainly in the underlying cortex, hippocampusPlease cite this article in press as: Chhor, V., et al. Role of microglia in a mous
http://dx.doi.org/10.1016/j.bbi.2016.11.001and striatum, and a qualitative representation is found in Fig. 1.
Specifically for Iba-1, numbers of positive cells were increased in
the cortex following TBI at P1 by 150% (contralateral
30.86 ± 2.24 versus ipsilateral 46.64 ± 2.41; n = 36) and in the stria-
tum by 350% (contralateral 12.05 ± 0.77 versus ipsilateral
47.23 ± 2.36; n = 36). We analysed the number of Iba-1 positive
cells by sex and found no difference between control values for
the cortex (contralateral male 25.21 ± 0.74, n = 20 versus contralat-
eral female 23.97 ± 1.17, n = 16; p = 0.35, t-test) or striatum (con-
tralateral male 11.68 ± 1.07, n = 17 versus contralateral female
12.47 ± 1.15, n = 16; p = 0.55, t-test), or in the response to injury
in the cortex (ipsilateral male 53.71 ± 2.31, n = 17 versus ipsilateral
female 51.66 ± 2.48, n = 16; p = 0.52, t-test) and striatum (ipsilat-
eral male 47.97 ± 3.38, n = 17 versus ipsilateral female
46.43 ± 3.37, n = 16; p = 0.76, t-test). As such, we grouped males
and females for the following analysis. The effects of TBI on the
expression of 20 cytokines and chemokines were measured in
the ipsilateral hemisphere at 6, 14 h and 24 h, and compared to
levels in sham animals (Fig. 2). Expression increased for markers
associated with each MG/MU phenotype at all three time points.
We observed that relative to levels in a sham hemisphere, the
pro-inflammatory/cytotoxic phenotype markers IL-1b and CCL3
(MIP1a) showed the greatest and most persistent increases in
expression over time (>5 fold). The prototypical anti-
inflammatory or reparatory/regenerative cytokine IL-4 and the
immunomodulatory cytokine IL-10 were also increased at all three
time points in the ipsilateral hemisphere. TNFa and IL-12 (p70)
were the only markers that did not significantly increase at any
time point.3.2. TBI induces MG/MU expression of markers of a regenerative/
immunomodulatory phenotype
CD11B-positive MG/MU were isolated from whole cortices
using MACS technology at 2, 6 and 14 h and 1 and 5 days post-
TBI, and gene expression of 12 phenotype markers was measured
(Fig. 3). Expression of the prototypical cytotoxic MG/MU markerse model of paediatric traumatic brain injury. Brain Behav. Immun. (2016),
Fig. 2. Expression of cytokines and chemokines from the ipsilateral hemisphere over time post-TBI. Genes are grouped based on predicted role in inflammation: cytotoxic
(CytoT), reparatory/regenerative (R-Regen), and immunomodulatory (Immu-M) based on (Colton, 2009; Prinz et al., 2011). Data are normalized to sham group expression
(Sham = 1) and are indicated as means ± SEM (n = 6–8 animals/group). Data were compared to the corresponding sham group using a Mann-Whitney U test. *p < 0.05,
**p < 0.01, ***p < 0.001.
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increase at any time point examined. The cross-phenotype marker
Cox-2 (cytotoxic-immunomodulatory) and IL1Rn, which has
immunomodulatory functions, were persistently increased by
TBI. Two additional immunomodulatory markers, SOCS3 and IL-
4ra, showed early increases, but by 1-day post-TBI were reduced
to below non-TBI levels. Among the reparatory/regenerative MG/
MUmarkers, Arg1 and Gal3 showed persistent increases following
TBI, but IGF-1 and CD206 were decreased.Please cite this article in press as: Chhor, V., et al. Role of microglia in a mous
http://dx.doi.org/10.1016/j.bbi.2016.11.0013.3. Blocking MG/MU activation with minocycline causes
improvements in neuropathology at 1 day post-TBI
Early brain injury was assessed via CCasp3 cell counts and
using ventricular dilatation, calculated as the ratio of the ventric-
ular size in the ipsilateral vs. the contralateral hemisphere.
Animals treated with minocycline had reduced numbers of
CCasp3-positive cells in the cortex, hippocampus and striatum
(Fig. 4C and D). In agreement with these data, minocyclinee model of paediatric traumatic brain injury. Brain Behav. Immun. (2016),
V. Chhor et al. / Brain, Behavior, and Immunity xxx (2016) xxx–xxx 7treatment led to less ventricular dilatation compared with the
untreated group at 1 day post-TBI (Fig. 4A and B). Sham groups
treated with either vehicle or minocycline displayed no change
in ventricular size and had very low levels of CCasp3-positive
cells (data not shown).
3.4. Improved neuropathology due to minocycline is accompanied by
reduced MG number and altered MG/MU activation
To characterize any relationship between the MG/MU inflam-
matory response and neuroprotection, 1 day following TBI, MG cell
numbers were quantified using Iba-1 immunolabeling and the
phenotype of isolated CD11B-positive MG/MU was assessed. AsFig. 3. Expression of phenotype markers by MG/MU isolated at various times post-TBI.
regenerative (R-Regen), and immunomodulatory based on (Colton, 2009; Prinz et al., 201
(n = 5–6 animals/group). Gene expression over time was analysed with a two way repeat
for each hemisphere at each time point. Summary of the ANOVA results are presented on
effects of TBI [HEMI]. Results of the post-test are indicated with: *p < 0.05, **p < 0.01, ***p
Please cite this article in press as: Chhor, V., et al. Role of microglia in a mous
http://dx.doi.org/10.1016/j.bbi.2016.11.001expected based on previous reports of the effects of minocycline,
the numbers of Iba-1-positive cells were decreased in the cortex,
hippocampus and striatum of minocycline-treated animals
(Fig. 5). Minocycline induced complex changes in the phenotype
and cytokine/chemokine expression of MG/MU that were isolated
post-TBI (Fig. 6). The cytotoxic phenotype markers iNOS and IL-6
were reduced from TBI only levels by minocycline treatment but
IL-1b was increased. Among repair/regeneration markers, treat-
ment with minocycline stimulated a further increase in the expres-
sion of Gal3 and Arg1, and reduced the typical loss of IGF1. Among
immunomodulatory markers, minocycline increased the expres-
sion of IL-1Rn above typical levels but led to an even greater
decrease in the expression of IL10.Genes are grouped based on predicted role in inflammation: cytotoxic, reparatory/
1). Data are normalized to sham group expression (Sham = 1) and are means ± SEM
ed measures ANOVA, with a Bonferroni post-test to compare the relative expression
each panel (effects of interaction between variable [INTx], effects of time [TIME] and
< 0.001.
e model of paediatric traumatic brain injury. Brain Behav. Immun. (2016),
Fig. 4. Minocycline improves neuropathology 1-day post-TBI. A) Quantification of ventricular volume at 1 day post-TBI, and B) representative images of cresyl-violet-stained
sections from both groups indicating ventricular size. C) Quantification of CCasp-3-positive cell number. D) Representative images of CCasp-3 immunolabeling in the striatum
from both groups, scale bar 50 lm. Data are indicated by means ± SEM (n = 9–18 animals/group), and PBS- and minocycline-treated groups were compared via a Student’s
t-test. *p < 0.05, **p < 0.01.
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treatment are lost by 5 days post-TBI
Immunolabeling for MAP2 and MBP were used as surrogates for
damage to neurons and myelination by oligodendrocytes respec-
tively. TBI decreased the volume of tissue immunolabeled for
MAP2 and MBP, and persistently caused ventricular dilatation in
the injured hemisphere at 5 days post-TBI (P14; Fig. 7). MAP-2
immunolabeling was similar to that reported previously in the
immature brain (Carlsson et al., 2011; Lingwood et al., 2008), dis-
playing a more diffuse pattern and with less cytoplasmic intensity
than in the adult. Despite improvements at 1-day post-TBI, at
5 days post-TBI, in animals treated with minocycline, ventricle size
was identical to that in PBS treated TBI animals (Fig. 7A). In accor-
dance with the ventricular data, the loss of MAP2 and MBP
immunolabeling was not prevented by treatment with minocy-
cline (Fig. 7B–E).4. Discussion and conclusions
4.1. Principal results and the TBI model
In our closed-contusion model of paediatric TBI, injury mod-
estly increased the levels of both pro- and anti-inflammatory
cytokines/chemokines in the brain as well as the number of MG.
Isolated MG/MU had only moderate changes in gene expression,Please cite this article in press as: Chhor, V., et al. Role of microglia in a mous
http://dx.doi.org/10.1016/j.bbi.2016.11.001and increases specifically in markers for the repair/regeneration
and immunomodulatory phenotypes. Blocking inflammation/MG/
MU activation with minocycline decreased MG number, reduced
expression of some pro-inflammatory cytokines but was only tran-
siently neuroprotective.
We chose for this study a closed-contusion weight-drop TBI
model as it has injury mechanisms similar to those seen in paedi-
atric TBI (Xiong et al., 2013). In particular, within the first 30 days
of life, at 7-day old, mice display the most widespread apoptotic
injury following TBI (Bittigau et al., 1999). This is also the period
of greatest vulnerability to excitotoxic lesion in the rodent
(Ikonomidou et al., 1989; McDonald et al., 1988) a likely effect of
the reduced compensatory anti-oxidant defences of the immature
as opposed to the adult brain (Fan et al., 2003). As apoptotic cell
death, excitotoxicity and oxidative stress play crucial roles in the
pathogenesis of TBI in the neonate (Ruppel et al., 2001; Zhang
et al., 2005); this adds weight to the relative usefulness of mod-
elling TBI at this period of rodent development.4.2. Cortical tissue damage and injury response following paediatric
TBI
Following TBI we observed increased total cortical expression of
cytokines and chemokines, as well as dilated ventricles and obvi-
ous tissue injury in the thalamus and hippocampus of the injured
hemisphere. These observations are generally in agreement withe model of paediatric traumatic brain injury. Brain Behav. Immun. (2016),
Fig. 5. Minocycline decreases MG cell number 1-day post-TBI. A) quantification of the number of Iba-1-positive cells at 1 day following TBI in PBS- and minocycline-treated
mice within the cortex, hippocampus and striatum. B) Representative Iba-1-positive cells in animals from each group from within the striatum, scale bar 50 lm. Data are
indicated by means ± SEM (n = 9–16 animals/group). PBS- and minocycline-treated groups were compared via a Student’s t-test. *p < 0.05.
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and humans (Helmy et al., 2011; Kaindl et al., 2007; Moretti
et al., 2016; Xiong et al., 2013). Specific comparisons across studies
are hampered by differences in models and methods, specifically
the use of protein versus gene analysis. However, specific compar-
isons for gene expression can be made to published gene array
data. In this context levels of almost all of the jointly reported
cytokines and chemokines are considerably lower in our model
than that previously reported in two adult rat models of controlled
cortical impact (Matzilevich et al., 2002; Raghavendra Rao et al.,
2003; White et al., 2013), and one rat model of fluid-percussion
injury (Truettner et al., 2005), but were comparable to that
reported in a model of adult rat bilateral prefrontal cortical contu-
sion (He et al., 2004). Protein levels for chemokines and cytokines
are also consistently and persistently high in previous reports from
adult models of contusion and blast-induced TBI (Bye et al., 2007;
He et al., 2004; Kumar et al., 2015; Williams et al., 2007). We sug-
gest that further work is needed to ascertain if any smaller magni-
tude of cortical pro-inflammatory cytokine release is linked to our
observation that neonatal TBI induces a predominantly reparatory/
regenerative or immunomodulatory MG/MU phenotype. As MG/
MU are the chief drivers of neuroinflammation, a predominantly
anti-inflammatory response might prevent cortical inflammation
reaching the levels seen in adult injury models, in which there is
a robust cytotoxic/pro-inflammatory MG profile (Kumar et al.,
2015).
We also wish to briefly discuss the effects of TBI in the con-
tralateral hemisphere. We noted that gene expression was lower
than sham level even in the contralateral hemisphere in MG/MU
for cytotoxic markers (including CD86 and CD32) and also for the
repair-regeneration marker CD206 and the immunomodulatory
marker SphK1. This type of remote gene expression change has
been previously reported in an adult cortical contusion model
where it was reported that these are not simply reduced magni-Please cite this article in press as: Chhor, V., et al. Role of microglia in a mous
http://dx.doi.org/10.1016/j.bbi.2016.11.001tude changes spilling over from the ipsilateral cortex but that some
effects are specific (White et al., 2013). Remote tissue changes
(such as in the cortex following spinal cord injury) are considered
to be crucial mediators of sensorimotor dysfunction and cognitive
impairments (Ajao et al., 2012; Kamper et al., 2013; Kim et al.,
2006). The diffusion of inflammatory products setting up a chain
reaction, signalling via gap junctions in astrocytes and changes in
neuronal activity patterns in distant areas are hypothesized to
underpin these remote effects. Disruption of the developmental
functions of MG (such as synaptogenesis) is considered to underpin
some of the injury associated with damage to the immature brain
at the injury site and in the remote regions, see (Tremblay et al.,
2011). Furthermore, on going changes in homeostatic functions
are associated with neurodegeneration such as in aging (Grabert
et al., 2016; Griffin et al., 2006; Hart et al., 2012; Lourbopoulos
et al., 2015). As such, additional longitudinal studies in this model
are warranted to explore the remote and persisting effects of TBI.
4.3. MG/MU phenotype in paediatric vs. adult TBI and other injury
models
This is the first study to assess the phenotype of ex-vivoMG/MU
over such a comprehensive time course (andwith somanymarkers)
after an acute neonatal injury. However, there are interesting tem-
poral studies on isolated MG in an adult TBI model (Kumar et al.,
2015), and total cortical inflammation in an adult TBI model
(Wang et al., 2013) although the methods of analysis vary making
it difficult to directly compare data. However, in adult TBI, the pro-
tein expressionof ex vivoMGfor classical pro-inflammatorymarkers
increased over time such that at +5 days all markers were robustly
increased, compared to our gene expressiondatawherein only three
cytotoxic markers were moderately increased, with no cohesive
time point of change. The authors of the adult TBI study sought to
describe the robust predominantly pro-inflammatory or mixede model of paediatric traumatic brain injury. Brain Behav. Immun. (2016),
Fig. 6. Effects of minocycline treatment on the expression of phenotype markers from MG/MU isolated 24 h post-TBI. Data are shown normalized to expression in a sham
group (Sham = 1) and as means ± SEM (n = 9–16 animals/group). Genes are grouped based on predicted role in inflammation: cytotoxic, reparatory/regenerative (R-Regen),
and immunomodulatory based on (Colton, 2009; Prinz et al., 2011). Data were compared with a two way ANOVA, with a Bonferroni post-test to compare the relative
expression for each hemisphere (PBS versus TBI). Summary of the ANOVA results are presented on each panel (effects of interaction between variable [INTx], effects of time
[TIME] and effects of TBI [HEMI]. Results of the post-test comparing each hemisphere are indicated with: *p < 0.05, **p < 0.01, ***p < 0.001.
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and immunomodulatory phenotype as ‘‘Mtran” (Kumar et al., 2015).
In our paediatric model, since cytotoxic MG/MU gene expression
was generally low, including at 5 days post-TBI, we conclude it is
unlikely that this phenotype occurs in this model, although we
would need to validate our data with the same FACS based protein
analysis. However, when comparing neonatal and adult studies it
is worth considering that robust age-dependent differences in MG/
MU gene expression have been reported (Bennett et al., 2016;
Butovsky et al., 2014). In brief, the stage of development is likely
important for MG/MU reactivity and is an important consideration
for studies of neuroinflammation.
Another key point in the interpretation of these data is the abil-
ity of cells to co-express markers, reflecting the in vivo complexity
of phenotype descriptors. Our gene expression analysis dose not
allow up to determine if there are discrete populations of cells
switching phenotype or cell co-expressing different category mar-
ker as has been previously reported in adult studies (Bedi et al.,
2013; Li et al., 2014; Vogel et al., 2013). Co-expression pattern
are likely in our paediatric TBI model, but from the paucity of gene
expression changes overall any robust co-expression of markers
seems unlikely.Please cite this article in press as: Chhor, V., et al. Role of microglia in a mous
http://dx.doi.org/10.1016/j.bbi.2016.11.0014.4. Mode of action of minocycline as a neuroprotective agent
Minocycline is a second-generation semi-synthetic tetracycline
that is best known for reducing pro-inflammatory responses via its
effects on MG/MU (Homsi et al., 2010; Kobayashi et al., 2013; Ng
et al., 2012). Minocycline has been used successfully to reduce
brain damage across a diverse range of injury/disease models, such
as multiple sclerosis (experimental autoimmune encephalitis),
term and preterm brain injury (excitotoxicity and hypoxia-
ischemia, respectively) and Alzheimer’s disease, for review see
(Garrido-Mesa et al., 2013). Minocycline successfully reduced TBI
severity at our early time point of 1 day post-lesion, despite there
being little pro-inflammatory response fromMG/MU. It is not clear
from the literature whether minocycline can act directly on astro-
cytes (Kernt et al., 2010; Yoon et al., 2012) to facilitate any effect.
Nevertheless, several pathological mechanisms involved in TBI
are counteracted by minocycline, possibly accounting for the
neuroprotection. These include that minocycline increases levels
of the anti-apoptotic protein Bcl-2 (Wang et al., 2004) and the
chelation of magnesium and calcium (Gonzalez et al., 2007) and
also decreases activation of MMPs (Koistinaho et al., 2005)
and caspase-1 and caspase-3 (Sanchez Mejia et al., 2001). Thee model of paediatric traumatic brain injury. Brain Behav. Immun. (2016),
Fig. 7. Lack of improvement in neuropathology in minocycline treated animals 5 days post-TBI. A) Quantification of ventricular size 5 days post-TBI and B) quantification of
the volume of tissue loss in the traumatized hemisphere 5 days post-TBI based on MAP-2 immunoreactivity, D) representative photomicrographs of MAP2-immunolabeled
sections, scale bar 50 lm. C) and E) quantification and representative images of the volume of white matter loss in the traumatized hemisphere based on MBP
immunoreactivity, scale bar 200 lm. Data are indicated by means ± SEM (n = 12–18 animals/group). PBS- and minocycline-treated groups were compared via a Student’s
t-test.
V. Chhor et al. / Brain, Behavior, and Immunity xxx (2016) xxx–xxx 11protective effect of inhibiting MMPs in this model of paediatric TBI
has been previously demonstrated (Sifringer et al., 2007).4.5. Reasons for absence of long-term neuroprotection by minocycline
This study is not the first to report a limited neuroprotective
effect of minocycline (Fernandez-Gomez et al., 2005; Fox et al.,
2005; Sriram et al., 2006; Yang et al., 2003). Of particular interest
is a transient neuroprotective effect reported in an adult closed-
contusion TBI model that is strikingly similar to what we observed.
In this adult TBI model, behavioural improvements and reduced
lesion volume at 1-day post-TBI were lost by 4 days post-TBI
(Bye et al., 2007). An early but transient therapeutic effect of
minocycline has also been reported following hypoxic-ischemic
injury in the mouse (Fox et al., 2005; Nijboer et al., 2010), indicat-
ing that this effect of minocycline is not specific to TBI. A limitation
of these previous studies and our current study is that we did not
test whether behavioural outcomes were improved, despite no
change in neuropathology. The concept of a protective phase of
the MG/MU response after injury has gained enormous support
from studies of adult and neonatal models (Faustino et al., 2011;
Hernandez-Ontiveros et al., 2013; Hu et al., 2012; Lalancette-
Hebert et al., 2007). We speculate that the lack of persistent neuro-
protection with minocycline in this model might be because
microglia are attempting to repair the brain. As such, there are
short-term positive effects (that might relate to positive effects
of minocycline on other cells Koistinaho et al., 2005), but whenPlease cite this article in press as: Chhor, V., et al. Role of microglia in a mous
http://dx.doi.org/10.1016/j.bbi.2016.11.001MG are prevented from attempting to repair the brain in the longer
term due to exposure to minocycline these positive gains are neu-
tralised by 5 days. What is apparent however is that as outlined in
a (non exhaustive) list of studies in Table 1 there are unclear influ-
ences on outcome of species (rat versus mouse) and treatment
regime (immediate/early only, versus immediate and continuing).
The multitude of differences in experimental conditions and out-
come measures preclude any firm conclusions on the influences
of these factors on the true neuroprotective ability of minocycline.5. Conclusions
In summary, despite cortical inflammation and cell death fol-
lowing TBI, MG/MU retain the expression of markers of an endoge-
nous repair and regenerative phenotype in this model. Also, there
are only moderate increases in total cortical inflammatory markers
compared to adult injury models. We identified that using minocy-
cline to modify the activity of MG/MU had positive early effects on
injury, but did not persistently improve outcome. This work adds
considerably to our understanding of neuroinflammation after
TBI in a neonatal model by suggesting that further therapy design
should focus on supporting repair and regeneration type MG/MU
activation states rather than blanket immunosuppression.Conflict of Interest Statement
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